Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02254278 · ClinicalTrials.gov registry record · Phase 2
Reduced-Dose Intensity-Modulated Radiation Therapy With or Without Cisplatin in Treating Patients With Advanced Oropharyngeal Cancer
A Phase 2 study of Tongue Carcinoma and Stage III Oropharyngeal Squamous Cell Carcinoma, sponsored by NRG Oncology.
- Completed
- Registry status
- Phase 2
- Development phase
- 316
- Enrollment target
- 20
- Study locations
NCT02254278 is a Phase 2 study of Tongue Carcinoma and Stage III Oropharyngeal Squamous Cell Carcinoma that has completed, run by NRG Oncology. The registered enrollment target is 316 participants. The trial reports 20 study locations across 3 states.
The verdict
NCT02254278, a Phase 2 study of Tongue Carcinoma and Stage III Oropharyngeal Squamous Cell Carcinoma, has completed, sponsored by NRG Oncology.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 316 participants
- Enrollment target
- 20
- Study locations
Study Summary
This randomized phase II trial studies the side effects and how well modestly reduced-dose intensity-modulated radiation therapy (IMRT) with or without cisplatin works in treating patients with oropharyngeal cancer that has spread to other places in the body (advanced). Radiation therapy uses high energy x rays to kill tumor cells. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether IMRT is more effective with or without cisplatin in treating patients with oropharyngeal cancer.
Conditions Studied
Interventions
- DRUG Cisplatin
- RADIATION IMRT 6 weeks
- RADIATION IMRT 5 weeks
Study Locations (20)
California
- Alta Bates Summit Medical Center-Herrick Campus - Berkeley
- Mills-Peninsula Medical Center - Burlingame
- Sutter Cancer Centers Radiation Oncology Services-Cameron Park - Cameron Park
- City of Hope Comprehensive Cancer Center - Duarte
- Marin General Hospital - Greenbrae
- UC San Diego Moores Cancer Center - La Jolla
- Kaiser Permanente Los Angeles Medical Center - Los Angeles
- Memorial Medical Center - Modesto
- Kaiser Permanente Oakland-Broadway - Oakland
- UC Irvine Health/Chao Family Comprehensive Cancer Center - Orange
- Palo Alto Medical Foundation Health Care - Palo Alto
- Stanford Cancer Institute Palo Alto - Palo Alto
- Kaiser Permanente-Rancho Cordova Cancer Center - Rancho Cordova
- Rohnert Park Cancer Center - Rohnert Park
- Sutter Cancer Centers Radiation Oncology Services-Roseville - Roseville
- The Permanente Medical Group-Roseville Radiation Oncology - Roseville
- Sutter Medical Center Sacramento - Sacramento
Arizona
- Banner MD Anderson Cancer Center - Gilbert
- Banner University Medical Center - Tucson - Tucson
Alabama
- University of Alabama at Birmingham Cancer Center - Birmingham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 316 participants |
| Start Date | 2014-10 |
| Est. Completion | 2025-09-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02254278
The ClinicalTrials.gov registry entry for NCT02254278 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 316 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NRG Oncology, which has 64 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Tongue Carcinoma appearing as the primary indexed condition, and to 3 interventions - of which Cisplatin is the first listed.
NCT02254278 reports 20 study locations spanning 3 distinct geographic areas - top geographies include California, Arizona, Alabama.
Frequently Asked Questions
What is clinical trial NCT02254278 about?
NCT02254278 is a clinical study titled "Reduced-Dose Intensity-Modulated Radiation Therapy With or Without Cisplatin in Treating Patients With Advanced Oropharyngeal Cancer". This randomized phase II trial studies the side effects and how well modestly reduced-dose intensity-modulated radiation therapy (IMRT) with or without cisplatin works in treating patients with oropharyngeal cancer that has spread to other places in the body (advanced). Radiation therapy uses high e...
What is the current status of trial NCT02254278?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 316 participants. The study started on 2014-10. Estimated completion is 2025-09-04.
What conditions does trial NCT02254278 study?
This clinical trial studies the following conditions: Tongue Carcinoma, Stage III Oropharyngeal Squamous Cell Carcinoma, Stage IVA Oropharyngeal Squamous Cell Carcinoma, Stage IVB Oropharyngeal Squamous Cell Carcinoma, Stage IVC Oropharyngeal Squamous Cell Carcinoma.
What interventions are being tested in trial NCT02254278?
The interventions under investigation include: Cisplatin (DRUG), IMRT 6 weeks (RADIATION), IMRT 5 weeks (RADIATION).
Who is sponsoring clinical trial NCT02254278?
This trial is sponsored by NRG Oncology, which has 64 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02254278 being conducted?
This trial has 20 study locations across Alabama, Arizona, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Tongue Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Tongue Carcinoma
All registered trials for this condition
Stage III Oropharyngeal Squamous Cell Carcinoma
All registered trials for this condition
Alabama
All trials with a study site in Alabama
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.